A Randomized Trial to Assess Anti-HIV Activity in Female Genital Tract Secretions and Soluble Mucosal Immunity Following Application of 1% Tenofovir Gel
2011

Study on Tenofovir Gel for HIV Prevention in Women

Sample size: 30 publication 10 minutes Evidence: high

Author Information

Author(s): Keller Marla J., Madan Rebecca P., Torres N. Merna, Fazzari Melissa J., Cho Sylvia, Kalyoussef Sabah, Shust Gail, Mesquita Pedro M. M., Louissaint Nicolette, Chen Jianmeng, Cohen Hillel W., Diament Erin C., Lee Anna C., Soto-Torres Lydia, Hendrix Craig W., Herold Betsy C.

Primary Institution: Albert Einstein College of Medicine

Hypothesis

Does the application of 1% Tenofovir gel increase anti-HIV activity in female genital tract secretions?

Conclusion

Tenofovir gel increased anti-HIV activity in cervicovaginal lavage without harming mucosal immunity.

Supporting Evidence

  • Women using Tenofovir gel showed significantly higher anti-HIV activity compared to those using placebo.
  • The anti-HIV activity persisted even when the virus was introduced in semen.
  • Tenofovir gel did not trigger an inflammatory response.
  • CVL concentrations of Tenofovir correlated significantly with anti-HIV activity.

Takeaway

The study tested a gel that helps prevent HIV in women, and it worked well without causing harm.

Methodology

30 women applied either 1% Tenofovir or placebo gel daily for 14 days, and anti-HIV activity was measured in cervicovaginal lavage.

Potential Biases

Potential bias in self-reported adherence to gel application.

Limitations

The study was short and conducted among sexually abstinent women, which may not reflect real-world use.

Participant Demographics

Healthy women aged 18-50 from the New York metropolitan area.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1371/journal.pone.0016475

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication